GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pangen Biotech Inc (XKRX:222110) » Definitions » Debt-to-Revenue

Pangen Biotech (XKRX:222110) Debt-to-Revenue : 0.15 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Pangen Biotech Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Pangen Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩2,100 Mil. Pangen Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩2 Mil. Pangen Biotech's annualized Revenue for the quarter that ended in Mar. 2024 was ₩13,899 Mil. Pangen Biotech's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.15.


Pangen Biotech Debt-to-Revenue Historical Data

The historical data trend for Pangen Biotech's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pangen Biotech Debt-to-Revenue Chart

Pangen Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.03 2.97 2.36 - 0.28

Pangen Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.35 0.22 0.15 0.15

Competitive Comparison of Pangen Biotech's Debt-to-Revenue

For the Biotechnology subindustry, Pangen Biotech's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pangen Biotech's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pangen Biotech's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Pangen Biotech's Debt-to-Revenue falls into.



Pangen Biotech Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Pangen Biotech's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2015.715 + 2.236) / 7315.125
=0.28

Pangen Biotech's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2099.509 + 2.236) / 13899.056
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Pangen Biotech Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Pangen Biotech's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Pangen Biotech (XKRX:222110) Business Description

Traded in Other Exchanges
N/A
Address
4Floor Innoplex 2-dong, 306 Sinwon-ro, Yeongtong-gu, Gyeonggi-do, Suwon-si, KOR, 16675
Pangen Biotech Inc is a biotechnology company. It is engaged in development of biosimilar products and technology transfer services for biologics development. It develops biosimilar products, such as EPO, recombinant factor VIII, G-CSF, etc.

Pangen Biotech (XKRX:222110) Headlines

No Headlines